AM-8553: A novel MDM2 inhibitor with a promising outlook for potential clinical development

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 4934-4935

  Bernard, Denzil ^a   Zhao, Yujun ^a   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 8553; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; NOTE; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

ACETIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PIPERIDONES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862291236     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3007068     Document Type: Note

References (9)

1. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53 Nat. Rev. Cancer 2002, 2 (8) 594-604
2. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop Genes Dev. 1993, 7 (7A) 1126-1132
3. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274 (5289) 948-953
4. Vassilev, L. T. MDM2 inhibitors for cancer therapy Trends Mol. Med. 2007, 13 (1) 23-31
5. Shangary, S.; Wang, S. Targeting the MDM2-p53 interaction for cancer therapy Clin. Cancer Res. 2008, 14 (17) 5318-5324
6. Vassilev, L. T. p53 activation by small molecules: application in oncology J. Med. Chem. 2005, 48 (14) 4491-4499
7. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303 (5659) 844-848
8. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (10) 3933-3938
9. Rew, Y.; Sun, D.; Gonzalez-Lopez De Turiso, F.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; Kopecky, D. J.; Li, Y.; Lo, M.-C.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2012, DOI: 10.1021/jm300354j.